GET DAILY SIGNALSTaysha Gene Therapies (TSHA) Q3 2026 Earnings Report Preview
Key Takeaways
- Taysha Gene Therapies is expected to report third-quarter 2026 results in early-to-mid November 2026, marking its next scheduled quarterly earnings update.
- Wall Street consensus points to a net loss of roughly $0.12 to $0.14 per share, with minimal revenue expected for the period.
- As a clinical-stage biotechnology company, Taysha's reported results matter less than updates on its lead candidate, TSHA-102 for Rett syndrome.
- Investors will focus on research and development (R&D) spending, cash runway, and any new clinical or regulatory milestones.
- Taysha Gene Therapies reported a net loss of $0.13 per share in the second quarter of 2026, and its shares have shown notable post-earnings volatility over the past year.
Earnings Context and Why It Matters
Taysha Gene Therapies (TSHA) is a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe central nervous system (CNS) diseases, led by TSHA-102 for Rett syndrome. Because the company generates little recurring revenue, its quarterly earnings are primarily a window into how efficiently it is funding clinical development. R&D expenses have climbed sharply as the pivotal REVEAL trial for TSHA-102 advances, making cash management a central theme for investors. With the stock trading well below its 52-week high and showing elevated short interest, the upcoming report will be closely watched for signals on trial timelines, spending discipline, and how far the company's cash reserves can support operations. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Consensus estimates call for Taysha to report a net loss of approximately $0.12 to $0.14 per share for the third quarter of 2026, with revenue expected to remain minimal—roughly $0.6 million to $0.8 million. For context, the company reported a net loss of $0.13 per share in the second quarter of 2026, with essentially no product revenue, as its clinical programs have not yet reached commercialization.
Rather than revenue or bottom-line figures, the metrics that matter most are R&D expense, net cash used in operations, and the reported cash balance. Taysha has emphasized that its cash position is expected to fund operations into 2028, so investors will scrutinize whether spending remains on track with that guidance. Updates on TSHA-102 dosing, patient enrollment, and any safety readouts will likely carry more weight than the headline loss itself.
Market Reaction and Investor Sentiment
Heading into the third-quarter report, sentiment around TSHA remains cautious but attentive to pipeline catalysts. The stock has experienced substantial post-earnings swings over the past year, with past releases generating outsized moves as investors react to clinical updates rather than financial line items. Elevated short interest also suggests a segment of the market is positioning against the shares, which can amplify volatility around the print. The key risk is an unchanged or worsening spending trajectory without a corresponding clinical catalyst, while the primary upside signal would be a clearer, on-time path for TSHA-102 through its pivotal trial.
Forward Outlook and Key Factors to Monitor
Following the report, investors should focus on guidance surrounding the company's cash runway and the pace of R&D spending. Taysha has previously indicated its cash is expected to fund operations into 2028, so any adjustment to that outlook would be a meaningful signal.
Clinical milestones for TSHA-102 in Rett syndrome remain the most important forward-looking catalysts. Updates on patient dosing, enrollment progress in the pivotal REVEAL trial, and any emerging safety or efficacy data will likely drive the stock more than the quarterly loss figure.
Broader industry conditions also matter. Biotechnology funding and sentiment can shift with interest-rate expectations and investor appetite for risk, influencing how the market values a pre-revenue, clinical-stage company. Cost discipline, manufacturing readiness for gene therapy, and regulatory feedback will be additional factors to watch in the quarters ahead.
Using Tickeron’s AI Screener for Biotech Research
In my own work, I turn to Tickeron’s AI Screener when scanning the biotechnology sector for patterns in spending trends and volatility. It allows quick filtering by industry, market cap, and technical signals, which helps surface comparable names and highlight where a stock like TSHA stands relative to peers. This kind of structured view supports a more informed look at both individual names and broader sector dynamics without replacing deeper fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TSHA sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for TSHA moved below the 200-day moving average on October 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 53 cases where TSHA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TSHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TSHA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TSHA's RSI Indicator exited the oversold zone, 30 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on TSHA as a result. In 71 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for TSHA just turned positive on October 21, 2026. Looking at past instances where TSHA's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.
Following a +7.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where TSHA advanced for three days, in 213 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
TSHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.441) is normal, around the industry mean (3.104). P/E Ratio (-9.976) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (333.333) is also within normal values, averaging (439.647).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. TSHA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TSHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement